Return to Home Mortality > Table > Interpret

Interpretation of Death Rates Data

Death Rate Report by State

Non-Hodgkin Lymphoma, 2019-2023

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Recentaapc

Explanation of Column Headers

Death Rate (95% Confidence Interval) - The death rate is based upon 100,000 people and is for 5 year(s). Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population (the Healthy People 2020 goals are based on rates adjusted using different methods but the differences should be minimal).

Recent Trends - This is an interpretation of the AAPC:

AAPC (95% Confidence Interval) - The Average Annual Percent Change is the change in rate over time. These AAPCs are based upon APCs that were calculated by Joinpoint Regression Program


Other Notes


Line by Line Interpretation of the Report


New York


New Jersey


North Dakota


District of Columbia


Puerto Rico


Alabama


Massachusetts


Arizona


New Hampshire


Florida


Illinois


Louisiana


Montana


Oregon


Pennsylvania


Nebraska


New Mexico


Wyoming


Georgia


Michigan


North Carolina


Tennessee


Idaho


Rhode Island


South Carolina


Utah


Wisconsin


Arkansas


California


Indiana


Maine


Ohio


Virginia


West Virginia


Delaware


Texas


Alaska


Colorado


Connecticut


Kentucky


Minnesota


Mississippi


Nevada


Oklahoma


Washington


Iowa


Hawaii


Missouri


South Dakota


Vermont


Kansas


Maryland





Notes:
Created by statecancerprofiles.cancer.gov on 03/23/2026 1:21 am.

State Cancer Registries may provide more current or more local data.

† Death data provided by the National Vital Statistics System public use data file. Death rates calculated by the National Cancer Institute using SEER*Stat. Death rates are age-adjusted to the 2000 US standard population (20 age groups: <1, 1-4, 5-9, ... , 80-84, 85-89, 90+).

Population counts for denominators are based on Census populations as modified by NCI.

The US Population Data File is used with mortality data.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.